Neurocrine Biosciences, Inc.
Moat Score — Neurocrine Biosciences, Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | INGREZZA is protected by 22 Orange Book patents running to 2040, with litigation settlements pushing generic competition out to March 2038 in most circumstances, and CRENESSITY carries seven years of orphan-drug exclusivity plus patents to 2041 - a textbook durable patent-and-regulatory-exclusivity moat. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Neurocrine owns no manufacturing capacity and spent roughly 35% of 2025 revenue on R&D and over 40% on SG&A; it competes on clinical differentiation and commercial execution, not on being a low-cost producer. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | INGREZZA effectively faces only one branded competitor (Teva's AUSTEDO) in tardive dyskinesia and Huntington's chorea, giving it real pricing power, though the IRA's Medicare negotiation of AUSTEDO's price and the eventual loss of Neurocrine's small-biotech exemption threaten to compress that power over time. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | As a traditional prescription biopharmaceutical business, Neurocrine's products carry no network effect; value does not increase as more patients or prescribers use the drug. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Physicians are generally reluctant to switch a tardive dyskinesia or CAH patient off a titrated, clinically stable regimen, and CRENESSITY's single-specialty-pharmacy distribution reinforces continuity, but neither creates the kind of structural lock-in seen in enterprise software or embedded financial infrastructure. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Tardive dyskinesia, Huntington's chorea, and congenital adrenal hyperplasia are relatively small, specialized patient populations that make the category commercially unattractive for the largest pharma companies to enter from scratch, giving incumbents like Neurocrine and Teva a durable two-player field. |